» Articles » PMID: 35625246

Bacteriophage-Enriched Galenic for Intrapericardial Ventricular Assist Device Infection

Overview
Specialty Pharmacology
Date 2022 May 28
PMID 35625246
Authors
Affiliations
Soon will be listed here.
Abstract

We report a case of severe outflow graft infection following left ventricular assist device (LVAD) implantation. A 51-year old male LVAD patient was readmitted to our hospital presenting signs of systemic infection. One year previously, LVAD implantation (HeartMate3, Abbott, Chicago, IL, USA) with concomitant patent foramen ovale closure had been performed in the context of end-stage heart failure due to dilative cardiomyopathy (INTERMACS III). The indication for LVAD-therapy was bridge-to-candidacy, since the patient did not instantly fulfill all criteria for cardiac transplantation. At admission, a PET-CT scan unveiled fluid accumulation, encircling the outflow-graft prosthesis (SUV 10.5) with contrast-enhancement involving the intrathoracic driveline (SUV 11.2). Since cardiac transplantation was not feasible, the patient underwent surgical revision. In the first step, redo sternotomy was performed with local debridement, including jet lavage. Intraoperative swabs confirmed bacterial infection with . Following this, the patient underwent negative pressure wound therapy (NPWT) with instillation using the V.A.C. VERAFLO system (KCI-3M, San Antonio, TX, USA) for a total of 19 days. Due to the severity of infection, local bacteriophage application was performed within the wound closure. In order to concentrate phage therapy at the infection site, phages were applied using a novel semi-fluid galenic. After wound closure, the patient was discharged with an uneventful course. A control PET-CT scan 3 months after discharge showed a significant decrease in infection (outflow graft: SUV 7.2, intrathoracic driveline: SUV 3.0) correlated with contrast enhancement. Bacterial infection of intrathoracic VAD components represents a severe and potentially life-threatening complication. If cardiac transplantation is not feasible, complex wound management strategies are required. Local bacteriophage therapy might be a promising addition to already established therapeutical options. In order to improve bacteriophage retention at the wound site, application of a viscous galenic might be beneficial.

Citing Articles

Phage Therapy for Cardiac Implantable Electronic Devices and Vascular Grafts: A Targeted Literature Review.

Passerini M, Petri F, Suh G Pathogens. 2024; 13(5).

PMID: 38787276 PMC: 11123972. DOI: 10.3390/pathogens13050424.


ventricular assist device infections: findings from ineffective phage therapies in five cases.

Aslam S, Roach D, Nikolich M, Biswas B, Schooley R, Lilly-Bishop K Antimicrob Agents Chemother. 2024; 68(4):e0172823.

PMID: 38470133 PMC: 10989018. DOI: 10.1128/aac.01728-23.


Pulmonary Vascular Resistance to Predict Right Heart Failure in Patients Undergoing Left Ventricular Assist Device Implantation.

Schramm R, Kirchner J, Ibrahim M, Rojas S, Morshuis M, Rudolph V J Clin Med. 2024; 13(2).

PMID: 38256596 PMC: 10816947. DOI: 10.3390/jcm13020462.


The Safety and Efficacy of Phage Therapy for Infections in Cardiac and Peripheral Vascular Surgery: A Systematic Review.

Simpson E, MacLeod C, Stacey H, Nagy J, Jones J Antibiotics (Basel). 2023; 12(12).

PMID: 38136718 PMC: 10740750. DOI: 10.3390/antibiotics12121684.


Successful Bacteriophage-Antibiotic Combination Therapy against Multidrug-Resistant Left Ventricular Assist Device Driveline Infection.

Racenis K, Lacis J, Rezevska D, Mukane L, Vilde A, Putnins I Viruses. 2023; 15(5).

PMID: 37243293 PMC: 10223274. DOI: 10.3390/v15051210.


References
1.
Hanff T, Birati E . Left Ventricular Assist Device as Destination Therapy: a State of the Science and Art of Long-Term Mechanical Circulatory Support. Curr Heart Fail Rep. 2019; 16(5):168-179. DOI: 10.1007/s11897-019-00438-x. View

2.
Bernhardt A, Schloglhofer T, Lauenroth V, Mueller F, Mueller M, Schoede A . Prevention and early treatment of driveline infections in ventricular assist device patients - The DESTINE staging proposal and the first standard of care protocol. J Crit Care. 2020; 56:106-112. DOI: 10.1016/j.jcrc.2019.12.014. View

3.
Tkhilaishvili T, Merabishvili M, Pirnay J, Starck C, Potapov E, Falk V . Successful case of adjunctive intravenous bacteriophage therapy to treat left ventricular assist device infection. J Infect. 2021; 83(3):e1-e3. DOI: 10.1016/j.jinf.2021.05.027. View

4.
Pienta M, Shore S, Pagani F, Likosky D . Rates and types of infections in left ventricular assist device recipients: A scoping review. JTCVS Open. 2022; 8:405-411. PMC: 9390679. DOI: 10.1016/j.xjon.2021.08.005. View

5.
Rojas S, Hanke J, Haverich A, Schmitto J . Chronic ventricular assist device support: surgical innovation. Curr Opin Cardiol. 2016; 31(3):308-12. DOI: 10.1097/HCO.0000000000000290. View